Lena A. Basile, Ph.D., J.D., President, Chief Executive Officer

Dr. Basile founded Neumedicines in 2003 and is the driving force behind its success. Dr. Basile wrote the original IL-12 technology patent applications and wrote and secured multiple funded peer-reviewed grants and contracts. To date, Dr. Basile has secured over $33 million in non-dilutive government funding for Neumedicines. Dr. Basile received her doctorate in chemistry from Columbia University in inorganic complex-DNA interactions. She then went on to complete postdoctoral studies at Yale University in the department of Molecular Biology and Biochemistry, where she studied protein-DNA interactions of several DNA-binding proteins including HIV-related proteins. Dr. Basile has over 20 years of scientific experience and also holds a doctorate in law from the University of Houston Law Center. She is a member of the State Bar of California and, prior to founding Neumedicines, practiced as an intellectual property attorney for 7 years.

Timothy K. Gallaher, Ph.D., Chief Analytics Officer

Dr. Gallaher is a co-founder of Neumedicines, and currently serves as the Chief Analytics Officer for the company. He was formerly Director of the Proteomic Core Facility, which is part of the USC School of Pharmacy. Dr. Gallaher has over 20 years of scientific experience since receiving his doctorate degree from the University of California at Santa Cruz. His background is in pharmacology, protein sciences, including proteomics, stem cell biology, and bioinformatics. His bioinformatics efforts led to the discovery of HSS1, a novel protein is a suppressor of tumor growth under development at Neumedicines.

Mr. Joseph Jou

In addition to serving on Neumeidicnes’ board, Mr. Joseph Jou serves as the Vice Chairman of American GreenPower; Director of BioCalth International, Inc.; Managing Member of Ruby Ridge, LLC; and as Chairman of Weal Investment, Inc. Mr. Jou also serves as Advisor of YiHai Property and Economic Advisor to the city of Weihai, Shandong, People’s Republic of China (PRC). Mr. Jou has previously served as Chairman of United Commercial Bank; Vice Chairman and Founder of First Continental Bank; and Chairman of Asian Business Association. Mr. Jou received his undergraduate degree from Feng Chia University (Taiwan).

Raphael Nir, Ph.D.

Dr. Nir has 17 years experience in the field of recombinant protein production and related processes since he obtained his doctorate in Biotechnology from Tel-Aviv University in Israel. He was formerly Associate Principal Scientist at Schering-Plough Research Institute, where he developed several novel processes related to protein production. Dr. Nir is also one of the inventors of the Wave Bioreactor technology. Currently, Dr. Nir is also the CEO of SBH Sciences, Inc. focused on the development and implementation of cell-based bioassays and efficient cell culture processes for the commercial production of recombinant cytokines and monoclonal antibodies. Dr. Nir has produced over 60 recombinant proteins and antibodies for commercial use in the research market, including recombinant human IL-12 (rhuIL-12).